Publisher
Springer International Publishing
Reference57 articles.
1. Ahmed, M., Barbachano, Y., Riddell, A., Hickey, J., Newbold, K. L., Viros, A., … Nutting, C. M. (2011). Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. European Journal of Endocrinology, 165(2), 315–322. https://doi.org/10.1530/eje-11-0129.
2. Baschieri, L., Castagna, M., Fierabracci, A., Antonelli, A., Del Guerra, P., & Squartini, F. (1989). Distribution of calcitonin- and somatostatin-containing cells in thyroid lymphoma and in Hashimoto’s thyroiditis. Applied Pathology, 7(2), 99–104.
3. Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., … Erlichman, C. (2014). A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. The Journal of Clinical Endocrinology and Metabolism, 99(5), 1687–1693. https://doi.org/10.1210/jc.2013-3713.
4. Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., … Santoro, M. (2004). Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene, 23(36), 6056–6063. https://doi.org/10.1038/sj.onc.1207810.
5. Carney, J. A., Sizemore, G. W., & Hayles, A. V. (1979). C-cell disease of the thyroid gland in multiple endocrine neoplasia, type 2b. Cancer, 44(6), 2173–2183. https://doi.org/10.1002/1097-0142(197912)44:6<2173::aid-cncr2820440630>3.0.co;2-0.